Patricia Ashton-Prolla, MD, PhD, FACMG
Professor
Institution: Hospital de Clinicas de Porto Alegre
Patricia Ashton-Prolla is a MD, PhD clinical geneticist and Professor in Genetics at the Federal University of Rio Grande do Sul (UFRGS) in Porto Alegre, Brazil. She coordinates the Cancer Risk Assessment Program at the University Hospital (Hospital de Clínicas de Porto Alegre) where she also holds the position of Director of Research since 2016. Her research activities focus in translational aspects of cancer genetics and cancer geneticcounseling. She has received funding from Brazilian Governmental Agencies, Susan G Komen for the Cure, GlaxoSmithKline, Welcome Trust and Organización Panamericana de la Salud. Dr. Ashton-Prolla holds active research collaborations with colleagues in South and Central America, the U.S., Canada, France, U.K. and Portugal. In the last 5 years she has authored or co-authored 57 scientific articles published in peer-reviewed journals, and directly supervised 8 postdoctoral fellowships, 13 PhD thesis and 25 MSc dissertations.
Randall W. Burt, MD
Senior Director for Prevention and Outreach
Institution: Huntsman Cancer Institute
Dr. Burt is Emeritus Professor of Medicine at the University of Utah and Emeritus Director of Prevention and Outreach at Huntsman Cancer Institute (HCI). He served as HCI’s Senior Director of Prevention and Outreach from February, 2001, through October, 2013, serving also as Interim Senior Director of Clinical Affairs from April, 2012, through March, 2013. He was Director of HCI’s High Risk Colon Cancer Clinic 2001-October, 2013, and was co-leader of the Cancer Center Support Grant’s Gastrointestinal Cancers Program from 2008 to 2013. He was co-leader of the Cancer Control and Population Sciences Program for five years. In addition, he served as Interim Executive Director of HCI for 15 months before re-assuming co-leadership of the Gastrointestinal Cancers Program. Other past administrative positions at the University of Utah include Chief of Medical Service at the Salt Lake City Veterans Administration Medical Center for two years and GI Division Chief at the University of Utah School of Medicine for six years. He is a leader in policy making for average- and high-risk colon cancer screening nationally and internationally, and has served as a member of the American Cancer Society National Advisory Committee on Colorectal Cancer, the Governing Board of the American Gastroenterological Association, and the Scientific Advisory Board of the World Health Organization Collaborating Center for the Prevention of Colorectal Cancer. He has served on the National Comprehensive Cancer Network Colorectal Cancer Screening Panel for six years and has chaired that committee from 2006 to the present. He has been on the advisory committee of the NIH Colon Cancer Familial Registry for 10 years, and was chairman for 5 years. His research and administrative work has been instrumental in establishing the colon cancer screening guidelines now used by all major health policy organizations, in particular those for high-risk familial and inherited colon cancer conditions. Dr. Burt is a clinical genetics investigator (gastroenterologist) whose career has involved research in the inheritance of colorectal cancer and the identification of colon cancer susceptibility genes. He was one of the first investigators to describe common inheritance of colonic adenomatous polyps segregating with colorectal cancer. He was involved with identifying the APC gene, describing the attenuated polyposis syndrome, developing strategies for genetic testing and surveillance for inherited and familial high-risk colon cancer, and designing, obtaining funding, and completing clinical trials for chemoprevention in sporadic and inherited colon cancer. Related projects include study of genetic environmental interactions and gene-gene interactions that give rise to colon cancer. His chief clinical focus is on cancer prevention through appropriate screening for colorectal and other cancers, with particular attention given to increased risk factors in inherited and non-inherited polyposis syndromes. Dr. Burt has been a principal investigator on several large NIH studies of colon cancer, including program projects, and has authored or co-authored numerous textbook chapters and articles in major scientific journals, several of which are considered seminal.
Stephanie Cohen, MS, LCGC
Director of the Genomic Medicine Institute
Institution: St. Vincent Hospital
Stephanie Cohen is a board-certified, licensed Genetic Counselor at St. Vincent Hospital in Indianapolis, IN, where she was instrumental in starting the Cancer Genetics Risk Assessment Program. She earned her MS degree in Genetic Counseling at the University of Michigan, and is a 2007 graduate of the City of Hope Intensive Cancer Course. She is active in several groups within the National Society of Genetic Counselors, including a position as chair of the Service and Delivery Model subcommittee regarding access and service delivery. Stephanie has been working to improve access to cancer genetic services by implementing a collaborative process with Genetic Counselor Extenders throughout the St. Vincent Health network across the state of Indiana. She serves on the Indiana Genetics Advisory Committee (IGAC) and is active in training genetic counseling students as an Adjunct Assistant Professor at Indiana University as a clinical supervisor and co-instructor for a Cancer Genetics course. She has multiple publications in the field of cancer genetics and genetic counseling service delivery.
Fergus J. Couch, PhD
Professor
Institution: Mayo Clinic
Fergus J. Couch, Ph.D., studies how genetic alterations influence the development of both breast and pancreatic cancer. The long-term goals of his research program are to develop methods that predict an individual's risk of developing breast cancer and facilitate cancer prevention efforts, as well as develop tests that improve selection of treatment for individuals with breast and pancreatic cancer. Specifically, inherited mutations that predispose to breast cancer are being identified by studying familial breast cancer. Separately, factors that influence the response of breast and pancreatic tumors to chemotherapy are being identified by characterizing early genetic alterations. Dr. Couch's team uses genomics and cell biological approaches and animal and mathematical models to address these goals.
Dr. Couch is affiliated with the Mayo Clinic Cancer Center and the Center for Individualized Medicine. His research is supported by the Breast Cancer Research Foundation, the Minnesota Partnership for Biotechnology and Medical Genomics, the National Institutes of Health (NIH), and an NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer.
Kevin Davies, PhD
VP Business Development & Publisher
Institution: C&EN American Chemical Society
Kevin Davies PhD is a scientific publisher, editor and author. He is the founding editor of Nature Genetics and Bio-IT World, and author of four popular science books including Cracking the Genome and The $1,000 Genome. He is currently EVP Strategic Development with Mary Ann Liebert Inc., where he is leading the launch of The CRISPR Journal, and the reccipient of a 2017 Guggenheim Fellowship.
Kevin studied biochemistry at Oxford University and obtained his PhD from St Mary’s Hospital Medical School in London working on the genetics of cystic fibrosis. After postdoc fellowships at MIT and Harvard Medical School, he joined the editorial staff of Nature magazine. He is the founding editor of Nature Genetics, the first of the Nature sister journal franchise. After spells at the Howard Hughes Medical Institute and Cell Press, where he served as Editor-in-Chief, he became the founding editor of Bio-IT World, a trade magazine covering the intersection of IT and life sciences. In 2013, Kevin joined the American Chemical Society as VP Business Development and Publisher of the weekly magazine Chemical & Engineering News. Kevin is the author of four popular science books: Breakthrough (co-authored with Michael White) on the race for the breast cancer gene; Cracking the Genome, an exploration of the Human Genome Project, translated into 16 foreign languages; and The $1,000 Genome, which explores advances in next-gen sequencing and personal genomics. He also served as genetics consultant on the 2014 movie Decoding Annie Parker. Davies is also a co-author of DNA: The Story of the Genetic Revolution (August 2017) with Nobel Laureate James D. Watson and Andrew Berry.
Lucy Langer, MD, MSHS
Co-Medical Director Cancer Genetics
Institution: Compass Oncology
Dr. Lucy Langer is the Practice President and practices Medical Oncology and Hematology with Compass Oncology in Portland, OR. She completed her undergraduate training in Economics at Columbia University and received her MD from Stanford University, where she also completed her internship, residency, and chief residency in Internal Medicine. Dr. Langer's Hematology/Oncology fellowship was completed at UCLA where she worked closely with Dr. Patricia Ganz in the Division of Cancer Prevention & Control Research. She is a graduate of the advanced course in cancer genetics through the City of Hope. Her areas of interest include Breast Cancer, Cancer Genetics, and Cancer Prevention & Survivorship. Dr. Langer is the co-Medical Director of the US Oncology Genetic Risk Evaluation and Testing Program.
Katrina Lowstuter, MS, CGC
Institution: USC/Norris Cancer Hospital
Katrina Lowstuter, MS,CGC, is a board certified genetic counselor who joined City of Hope in May of 2005 from the Huntsman Cancer Institute in Salt Lake City, Utah, where she developed her interest and expertise in hereditary colon cancer syndromes. In 2003, Ms. Lowstuter was awarded a grant from the National Society of Genetic Counselors to evaluate the status of hepatoblastoma screening for children at risk for familial adenomatous polyposis. Additional areas of research includes surveying primary care physicians to obtain their knowledge and perspectives regarding genetic discrimination. Ms. Lowstuter is a graduate of the University of Colorado Genetic Counseling Masters Program. She is a member of the National Society of Genetic Counselors, the American Society of human Genetics and the Collaborative Group of the Americas, an international consortium focused on hereditary gastrointestinal cancer research. Ms. Lowstuter currently works at University of Southern California Norris Cancer Hospital.
Patrick Lynch, MD
Professor, Department of Gastroenterology, Hepatology, & Nutrition
Institution: The University of Texas MD Anderson Cancer Center
Dr. Patrick Lynch is a gastroenterologist and scientist with specific expertise in cancer risk for mismatch repair gene mutation carriers. He is a Professor of Medicine in the Department of Gastroenterology, Hepatology and Nutrition at UT-MD Anderson Cancer Center in Houston, Texas. Dr. Lynch received his Law degree and degree in Medicine from Creighton University. His internship and residency were at the University of Arkansas for Medical Sciences. He completed his Fellowship in Gastroenterology at Baylor College of Medicine in Houston, Texas. Dr. Lynch provides surveillance for patients and families with hereditary colorectal cancers, and is actively involved in the counseling and management of these patients and families. He has led or collaborated on multiple NIH- and industry-funded studies in hereditary colorectal cancers, including basic science, clinical, chemoprevention and behavioral studies. He is a member of Council for and past President of the International Society for Gastrointestinal Hereditary Tumors (INSIGHT) and is past President of the Collaborative Group of the Americas on Inherited Colorectal Cancer. He was recently awarded a grant under the UTMDACC “Moonshot” program for further development of a web-based registry for familial cancer families.
Therese M. Mulvey, MD
Physician in Chief / Medical Oncologist
Institution: MA General Hospital
Dr. Mulvey has dedicated her career to providing state-of-the-art community based care for cancer patients. Her philosophy is to empower patients to receive high-quality care in their own communities, with shared decision making among specialists and patients. As the Director of Breast Medical Oncology at MGH/ North she oversees programs that are committed to ensuring patients have access to high-quality oncology services and leading-edge clinical cancer research. Dr. Mulvey earned her medical degree at Tufts University School of Medicine. She completed fellowships in hematology/ oncology at Massachusetts General Hospital as well as Tufts-New England Medical Center, where she also completed her residency. Dr. Mulvey is board certified in medical oncology and internal medicine. Areas of interest: cancer genetics and breast cancer.
Karen Tedesco, MD
Chief, Clinical Genetics Service
Institution: NY Oncology Hematology
Dr. Tedesco earned her MD from SUNY Health Science Center in Syracuse, NY and graduated magna cum laude. She completed an Internal Medicine residency at University of Michigan Medical Center where she earned a SPORE (Specialized Program of Research Excellence) student grant and received the House Officer Research Award for her Prostate Cancer Genetics project. Dr. Tedesco completed her Hematology and Oncology fellowship at Vanderbilt University Medical Center. Dr. Tedesco is board certified in Internal Medicine, Hematology, and Oncology and a member of many professional societies including AOA medical Honor Society, AMA, ASCO, and ASH. Dr. Tedesco has been an attending physician with NY Oncology Hematology since completing fellowship and is vice president of the Board of Directors. She is the program director for the NYOH Hereditary Cancer Risk Assessment Program and the NYOH Physician Mentoring Program. Dr. Tedesco is a member of the USON Breast Cancer Research Committee and local PI for many breast cancer clinical trials. She is co-director of the NYOH/Albany Medical College annual Translational Research Symposium and regularly teaches medical students and residents. Dr. Tedesco practices general Hematology and Oncology with a particular interest in breast cancer. She is regularly involved in community based education and outreach events.
Kenneth Offit, MD, MPH
Chief, Clinical Genetics Service
Institution: Memorial Sloane-Kettering Cancer Center
Kenneth Offit M.D.,M.P.H. is Chief of the Clinical Genetics Service at Memorial Sloan-Kettering Cancer Center, a Member of Cancer Biology and Genetics Program at the Sloan-Kettering Institute, and a Professor of Medicine and Public Health at the Weill Cornell Medical College of Cornell University. He is a graduate of Princeton University, the Harvard School of Public Health, and the Harvard Medical School. In 1996, his research group discovered the most common genetic mutation associated with inherited breast and ovarian cancer, occurring among Jews of European ancestry. In 2002, his group was the first to prospectively measure the impact of preventive ovarian surgery in individuals carrying BRCA mutations and he led the first genome wide association study of BRCA2 breast cancer. In 2013 his group described a new genetic syndrome of inherited childhood lymphoblastic leukemia. He is currently using next generation sequencing to define genomic markers of risk for leukemia, lymphoma, breast, ovarian and prostate cancer. Dr Offit was honored with the 2013 American Society of Clinical Oncology-American Cancer Society award for his work in genetics and cancer prevention. He is currently a member of the Board of Scientific Counselors of the U.S. National Cancer Institute, a genome advisory panel to the U.S. C.D.C., as well as co-Chair of the Germline Cancer Working Group of the Clinical Genome Resource of the National Human Genome Research Institute.
Mark E. Robson, MD
Clinic Director, Clinical Cancer Genetics Services
Institution: Memorial Sloan-Kettering Cancer Center
Mark Robson, MD is a Member and Attending Physician of the Clinical Genetics and Breast Medicine Services in the Department of Medicine at Memorial Sloan Kettering Cancer Center. He is also Professor of Medicine at Weill Cornell Medical College. He received his B.Sc. from Washington and Lee University and his M.D. from the University of Virginia. He performed residency and fellowship training at Walter Reed Army Medical center before coming to Memorial Sloan-Kettering in 1996. He is currently the Clinic Director of the Clinical Genetics Service. He serves on the Cancer Prevention and Ethics Committees of ASCO, is an Associate Editor for JNCI and is on the editorial board of the Journal of Clinical Oncology. Dr. Robson’s research is primarily directed toward the improving the integration of genetic information into the clinical management of women with breast cancer. He and his colleagues have conducted a number of studies examining outcomes in women with hereditary breast cancer to better define the risks and benefits of treatments such as breast conserving therapy and adjuvant chemotherapy in this group. He is also coordinating studies of PARP inhibitors in women with BRCA mutation-associated breast cancer. He and his coworkers have also conducted a number of studies examining the effectiveness of screening interventions such as breast MRI or ovarian cancer screening in women at hereditary risk. He is also investigating the optimal integration of new genetic technologies, such as genomic profiling and multi-gene testing, into the care of women at risk for breast cancer.
Patricia Rodriguez, MD
Cancer Genetics Specialist
Institution: Virginia Cancer Specialists
Dr. Rodriguez attended Johns Hopkins University where she was awarded a Bachelor of Science degree with honors in biomedical engineering. She received her medical degree from Albert Einstein College of Medicine where she was a member of the Alpha Omega Alpha Honors Medical Society. She completed her residency in Internal Medicine at Mount Sinai Hospital in New York and fellowship in Hematology and Oncology at George Washington Medical Center in Washington, D.C. She is board certified in Internal Medicine, Hematology and Oncology.
Dr. Rodriguez practices hematology and oncology in Arlington, VA. She is a member of several professional organizations including the American Society of Hematology and the American Society of Clinical Oncology. She is on the board of the Arlington Free Clinic and the Arlington County Medical Society.
Born in Montevideo, Uruguay, Dr. Rodriguez speaks both fluent Spanish and French.
Christina Rybak, MS, LCGC
Institution: Human Longevity
Christina Rybak, MS, LCGC is a board-certified licensed genetic counselor with experience in consumer genomics and hereditary cancer. She graduated from the University of South Carolina Genetic Counseling Training Program in 2006. She has a bachelor’s degree in English from Duke University. She worked as a cancer genetic counselor at Fox Chase Cancer Center 2008-2014, then at City of Hope 2014-2017. In her current role at Human Longevity, she provides genetic counseling for elective genome sequencing results including single gene Mendelian variants, pharmacogenomics, ancestry, GWAS and health traits. She has co-authored multiple papers about oncology and genetics, including topics such as colorectal cancer risk assessment, communication of genetic test results and follow-up needs of individuals with hereditary syndromes.
Thomas Slavin, MD, FACMG, DABMD
Senior Vice President of Medical Affairs for Oncology
Institution: Myriad Genetics
Dr. Slavin is Senior Vice President of Medical Affairs for Oncology at Myriad Genetics. He is a physician-scientist, triple-board-certified in clinical genetics, molecular diagnostics and pediatrics. Most recently, he served as assistant professor in the departments of Medical Oncology & Therapeutics Research and Population Sciences at City of Hope National Medical Center. Dr. Slavin graduated medical school with Alpha-Omega-Alpha-honors from the University of South Florida. He completed his residency programs at Case Western Reserve in Cleveland, Ohio; this training included a postdoctoral research year in genetic epidemiology. He has also completed graduate course work towards a Masters degree in clinical research through the University of Southern California. He is an active member of the American Association of Cancer Research, the American Society of Clinical Oncology (ASCO), the American Society of Human Genetics, the Collaborative Group of the Americas on Inherited Colorectal Cancer, and is a fellow of the American College of Medical Genetics and Genomics. He has served on National Comprehensive Cancer Network (NCCN)committees for both the genetics of and screening for colorectal cancer. He has served on three ClinGen expert working group committees for variant classification of breast, gastrointestinal and ovarian cancer predisposition genes. Focused on expanding genetics education for cancer care providers, Dr. Slavin has helped shape both ASCO University as well as City of Hope’s hereditary genomics training program. He is a well-published researcher in the field of medical genetics, including over 60 journal articles, multiple book chapters, and numerous presentations at national and international medical meetings. He has been involved in many national cancer research grants, and was a 2018 National Institutes of Health (NIH) K08-career development grant awardee.
Louise C. Strong, MD
Professor of Cancer Genetics
Institution: The University of Texas MD Anderson Cancer Center
Louise Strong, M.D., is best known for her scientific leadership and vision in pursuing studies of the genetic components and late effects of childhood cancer. She is a pioneer in advancing our understanding of cancer-prone disorders, with seminal discoveries into the genetic basis of Wilms tumor, retinoblastoma, and Li-Fraumeni syndrome. In 1981, Dr. Strong became the first woman faculty member at MD Anderson to be named to an endowed professorship, which now is the Sue and Radcliffe Killam Chair. Dr. Strong graduated from The University of Texas Medical Branch in Galveston with the long-term goal of conducting research in human genetics. Her interest in childhood cancer genetics originated with her postdoctoral work with Alfred Knudson, Jr., M.D., Ph.D., where they discovered that a subset of cancers might be due to the loss of suppressor genes rather than the acquisition of oncogenes. This research provided the sustained foundation for cytogenetic and molecular biological studies that extended their hypothesis to other hereditary tumors and propelled Dr. Strong to the forefront in the field of human genetics. Dr. Strong focused her research on childhood cancer, reasoning that children have not had the years of exposure to potential cancer causing agents as adults, and hence might represent a better model for genetic studies. She is best known for her work on childhood cancers, retinoblastoma, Wilms tumor of the kidney and Li Fraumeni syndrome, an inherited predisposition to multiple tumor types in children and young adults. The findings from this work have confirmed her idea that genes predisposing to cancer in rare hereditary cancers are the same genes altered in the more common non-hereditary cancers. Her team includes molecular and statistical genetics, with increasing opportunities in the new genomics era. Her current work with risk modifiers not only helps to explain the variation in risk both within and across families with genetic mutations predisposing to cancer, and individuals in the general population, but for long term impact is more significant in identifying pathways that may provide drug targets. Her clinical commitment is also in genetics, providing genetic counseling to high risk families, especially those with childhood or young onset cancer. It has been a nice complement to the research that led to the opportunity for genetic testing and counseling, and provides a "reality check" in terms of the research. She also is involved in the training of graduate students, genetic counselors, and oncology fellows. Dr. Strong is a recognized leader in her field as evidenced by her service on numerous advisory committees and recognition for her accomplishments. She has served on many review groups and policy-making committees of the National Cancer Institute, including her six-year term on National Cancer Advisory Board. In 1996-97, Dr. Strong served as President of the American Association of Cancer Research, the largest cancer research organization in the world. Her term as president was noteworthy for her leadership of a strategic planning process conducted by the Board of Directors. As a result of these discussions, the AACR embarked on an ambitious program that continues today to make the expertise of its members available to the lay public, government officials, cancer survivors, and the media. Dr. Strong has received many awards for her work including the first annual faculty achievement award for cancer prevention in 1992, the 1997 Ashbel Smith Distinguished Alumna of the University of Texas Medical Branch at Galveston, and the Distinguished Texas Geneticist Award from the Texas Genetics Society for 1997. In addition, the Retina Research Foundation of Houston has honored her work on retinoblastoma many times. In 1999, Dr. Louise Strong was honored with the Charles A. LeMaistre Outstanding Achievement Award in Cancer at MD Anderson Cancer Center.
Jeffrey N. Weitzel, MD
Professor of Oncology and Population Sciences
Jeffrey N. Weitzel, MD, is board Certified in Medical Oncology and Clinical Genetics, and founded the Clinical Cancer Genomics Community Research Network. He co-founded the Clinical Cancer Genomics Community of Practice with Dr. Blazer. A Breast Cancer Research Foundation Scholar and an honorary Professor of Oncology for the Latin American School of Oncology, he is also the ASCO Conquer Cancer Research Professor in Breast Cancer Disparities. At the vanguard of precision prevention, Dr. Weitzel’s multidisciplinary clinical, research, and training experience emphasize translational research in cancer disparities, genomic cancer risk assessment, chemoprevention, targeted therapy, clinical and psychosocial outcomes, genetic epidemiology and health services research, with a focus on underserved populations. Dr. Weitzel received the American Society of Human Genetics Arno Motulsky-Barton Childs Award for Excellence in Human Genetics Education.
Sharon Wilczynski, MD, PhD
Director, Anatomic Pathology and Cytology
Institution: City of Hope Comprehensive Cancer Center
Sharon P. Wilczynski, M.D., Ph.D., is one of City of Hope’s leading experts in gynecologic pathology. Throughout her career, she has been involved in multiple investigations studying genetic causes and potential treatments for cervical and ovarian cancers, with particular emphasis on the role of human papillomaviruses (HPVs) in the etiology of cervical and other cancers. Currently, Dr. Wilczynski is involved in several group clinical trials testing new therapies for patients with ovarian, endometrial and breast cancers. Her studies are funded by the National Institutes of Health, the California Cancer Research Program and the Southwest Oncology Group. In addition to her research, Dr. Wilczynski is very active in national and local medical and scientific bodies. She currently serves as chair of the Gynecologic Pathology subcommittee for the Southwest Oncology Group, and is a member of the National Comprehensive Cancer Network Committee for Determining Practice Guidelines for Cervical Cancer Screening.
Janet L. Williams, MS, LGC
Director, Research Genetic Counselors
Institution: Genomic Medicine Institute, Geisinger Health System
Janet L. Williams, MS, LGC obtained a Master’s Degree in Medical Genetics at the University of Wisconsin-Madison in 1979. Ms. Williams attended the Advanced Training Program offered through the Institute for Health Care Delivery Research at Intermountain Healthcare. Ms. Williams initiated the Cancer Genetic Counseling program at Intermountain Healthcare. She joined Geisinger in 2012, and is now Director of Research Genetic counselors. She has been involved in several research efforts including the clinical research study offering Whole Genome Sequencing for Undiagnosed Children. Ms. Williams is an Investigator in a project funded through the Patient Centered Outcomes Research Institute (PCORI) to develop genome sequencing result reports for patients and providers that enhanced communication and and shared decision making between clinicians and patients. Ms. Williams is now actively involved in a variety of efforts designed to improve the reach of Cascade Screening, particularly involving the three top tier genomic conditions recognized by the CDC, i.e. HBOC. Lynch and FH. In addition to the research position, Ms. Williams is employed part-time by Geisinger Health Plan to support development of medical policy to determine appropriate coverage of genetic testing, genetic counseling and genetic service delivery within Geisinger.
Marc S. Williams, MD, FAAP, FACMG
Director of the Genomic Medicine Institute
Institution: Genomic Medicine Institute of the Geisinger Health System
Marc S. Williams, MD, FAAP, FACMG, FACMI is a clinical geneticist and informaticist. As of January 2012, he has been the director of the Genomic Medicine Institute of the Geisinger Health System in Danville, Pennsylvania. He is the co-PI of the Geisinger Electronic Medical Records in Genomics (eMERGE) project and is the medical director of the whole genome sequencing clinical research project. He is site PI and leads the EHR integration workgroup of the NHGRI funded ClinGen project. He represents Geisinger Health System on the NHGRI Genomic Medicine working group. He has participated in the Personalized Medicine Workgroup of the Department of Health and Human Services’ American Health Information Community Task Force, chaired the CDC’s EGAPP Stakeholder’s Group and was a member of the Secretary’s Advisory Committee for Genetics, Health and Society. He is a member of the EGAPP working group. He is a past member of the ACMG Board of Directors, and served as Vice-President for Clinical Genetics. He is past chair of the ACMG Committee on the Economics of Genetic Services and founded the ACMG Quality Improvement Special Interest Group. He is a member of the Scientific Advisory Board of the Clinical Pharmacogenetic Implementation Consortium (CPIC) and a member of the CPIC informatics committee and has participated in guideline creation and review for that group. He recently joined the Scientific Advisory Board of the NIH Undiagnosed Diseases Project. He is boarded in clinical informatics and is a member of the AMIA genomics and translational bioinformatics workgroup and was Geisinger’s representative to the Clinical Decision Support Consortium. He was elected a fellow of the American College of Medical Informatics in 2016. He has authored over 130 articles on a variety of topics including the economic evaluation and value of genetic services, implementation of genomic medicine and the use of informatics to facilitate genomic medicine.